Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial (vol 295, pg 2727, 2006)

被引：0
|
作者：
Vogel, V. G.
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 296卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2926 / 2926
页数：1
相关论文
共 15 条
  • [1] Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial (vol 295, pg 2727, 2006)
    Vogel, V. G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (09): : 973 - 973
  • [2] Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
    Vogel, Victor G.
    Costantino, Joseph P.
    Wickerham, D. Lawrence
    Cronin, Walter M.
    Cecchini, Reena S.
    Atkins, James N.
    Bevers, Therese B.
    Fehrenbacher, Louis
    Pajon, Eduardo R., Jr.
    Wade, James L., III
    Robidoux, Andre
    Margolese, Richard G.
    James, Joan
    Lippman, Scott M.
    Runowicz, Carolyn D.
    Ganz, Patricia A.
    Reis, Steven E.
    McCaskill-Stevens, Worta
    Ford, Leslie G.
    Jordan, V. Craig
    Wolmark, Norman
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2727 - 2741
  • [3] The effects of tamoxifen versus raloxifene on the risk of developing noninvasive breast cancer in the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial.
    Vogel, V. G.
    Costantino, J. P.
    Wickerham, D. L.
    Wolmark, N.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S16 - S16
  • [4] Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial (vol 295, pg 2742, 2006)
    Land, S. R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (09): : 973 - 973
  • [5] Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
    Land, Stephanie R.
    Wickerham, D. Lawrence
    Costantino, Joseph P.
    Ritter, Marcie W.
    Vogel, Victor G.
    Lee, Myoungkeun
    Pajon, Eduardo R.
    Wade, James L., III
    Dakhil, Shaker
    Lockhart, James B., Jr.
    Wolmark, Norman
    Ganz, Patricia A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2742 - 2751
  • [6] The NSABP Study of Tamoxifen and Raloxifene (STAR) trial (vol 9, pg 51, 2009)
    Vogel, Victor G.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (03) : 388 - 388
  • [7] The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study.
    Wickerham, D. L.
    Costantino, J. P.
    Vogel, V.
    Cronin, W.
    Cecchini, R.
    Atkins, J.
    Bevers, T.
    Fehrenbacher, L.
    Mccaskill-Stevens, W.
    Wolmark, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2S - 2S
  • [8] Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer
    Wickerham, Donald Lawrence
    Cecchini, Reena S.
    Vogel, Victor G.
    Costantino, Joseph P.
    Cronin, Walter M.
    Bevers, Therese Bartholomew
    Fehrenbacher, Louis
    Pajon, Eduardo R.
    Wade, James Lloyd
    Robidoux, Andre
    Margolese, Richard G.
    James, Joan M.
    Runowicz, Carolyn D.
    Ganz, Patricia A.
    Reis, Steven E.
    McCaskill-Stevens, Worta J.
    Ford, Leslie G.
    Jordan, V. Craig
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2
    Vachon, Celine M.
    Schaid, Daniel J.
    Ingle, James N.
    Wickerham, D. Lawrence
    Kubo, Michiaki
    Mushiroda, Taisei
    Goetz, Matthew P.
    Carlson, Erin E.
    Paik, Soonmyung
    Wolmark, Norman
    Nakamura, Yusuke
    Wang, Liewei
    Weinshilboum, Richard
    Couch, Fergus J.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (02) : 517 - 523
  • [10] The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 Breast Cancer Prevention Study
    Ganz, P. A.
    Land, S. R.
    Wickerham, D. L.
    Lee, M.
    Ritter, M.
    Vogel, V.
    Pajon, E.
    Wade, J. L.
    Costantino, J. P.
    Wolmark, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 933S - 933S
12